Honeywell International Inc. HON is on the verge of a golden moment — literally. The stock is just about to make a Golden Cross , a classic technical indicator where the 50-day moving average crosses above the 200-day, signaling a potential bullish turn.

NEE's carbon-free nuclear power is expected to boost grid stability, cut emissions and support long-term clean energy growth.

Allegion (ALLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Popular (BPOP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agnico (AEM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GORILLA TECH GP (GRRR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Royal Bank (RY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Allison Transmission (ALSN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Does Postal Realty Trust (PSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Virtu Financial (VIRT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Peakstone Realty Trust (PKST) have what it takes to be a top stock pick for momentum investors? Let's find out.

AUNA's integrated LatAm healthcare platform is undervalued due to short-term execution, not structural flaws. The payor-provider model drives superior margins, cost efficiencies, and creates a powerful ecosystem with strong operating leverage, especially in underutilized Mexican assets. Management is actively addressing physician onboarding and payor mix, with insurance-led strategies poised to drive patient volume and profitability recovery.

LOS ANGELES, June 23, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”).

LOS ANGELES, June 23, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) securities between May 2, 2024, to May 6, 2025, inclusive (the “Class Period”).

LOS ANGELES, June 23, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 1, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, inclusive (the “Class Period”).

LOS ANGELES, June 23, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Krispy Kreme, Inc. (“Krispy Kreme” or the “Company”) (NASDAQ: DNUT) securities between February 25, 2025 and May 7, 2025, inclusive (the “Class Period”).

Nebius is the first European cloud to offer NVIDIA Blackwell GPUs, leveraging early capital and strategic partnerships to capture sovereign AI market share. Cheap convertible debt, early hardware access, and data moat from Toloka position Nebius for rapid growth, margin expansion, and geopolitical advantage. Execution risk and regulatory uncertainty exist, but Nebius' capital structure, pre-sold inventory, and ARR momentum mitigate downside versus peers like CoreWeave.

Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing regulatory milestones could further drive shareholder value.

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.